Lawrence M. Alleva, Director at Adaptimmune Therapeutics PLC (ADAP), bought 12,900 shares at $1.89 ($24K) on 2020-06-09, disclosed to the SEC on 2020-06-11.
Open-market purchase of $24k ADAP by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| ADAP | BUY | 2021-06-03 | $10K | — | Filing → |
| GRTX | BUY | 2021-06-03 | $35K | — | Filing → |
| GRTX | BUY | 2020-11-17 | $24K | — | Filing → |